AstraZeneca PLC - Research and Development

AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Research-and-Development" stands at 13.86 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

AstraZeneca PLC's third quarter result of 3.66 Billion USD for the item "Research and Development" represents an increase of 3.26 percent compared to it's second quarter result.

Also, AstraZeneca PLC's third quarter result of 3.66 Billion USD for the item "Research and Development" represents an increase of 15.90 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), AstraZeneca PLC's third quarter result of 13.86 Billion USD for the item "Research and Development" represents an increase of 3.76 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 18.55 percent compared to the value the year prior.
The 1 year change in percent is 18.55.
The 3 year change in percent is 51.46.
The 5 year change in percent is 143.59.
The 10 year change in percent is 140.96.

The Serie's long term average value is 7.06 Billion United States Dollars. It's latest available value, on 09/30/2025, is 96.36 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 09/30/2013, to it's latest available value, on 09/30/2025, is +194.05%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.